Peng Li, Lv Chong-Shan, Zhao Yun, Chen Shao-Dong, Huang Yang, Lu Da-Wei, Huang Shu-Qiong, Yang Zong-Bao, Qian Lin-Chao, Wen Lei
Department of Traditional Chinese Medicine, Medical College, Xiamen University, Xiamen 361102, China.
Oncotarget. 2017 Jul 7;8(47):82196-82206. doi: 10.18632/oncotarget.19072. eCollection 2017 Oct 10.
The aim of this study was to explore potential immunoregulatory mechanisms underlying the suppressive effect on atherosclerosis of QiShenYiQi pill (QSYQ).
Male ApoE mice were maintained on a Western-type diet and QSYQ treatment for eight weeks. Determination of atherosclerosis demonstrated that QSYQ attenuated plaque formation and decreased the level of blood low-density lipoproteins-cholesterol. QSYQ treatment did not affect body weight but reduced the ratio of liver weight and body weight. Western blots of liver showed that QSYQ increased the expression of liver X receptor alpha and ATP-binding cassette sub-family G member 5. Western blots of atherosclerotic aorta revealed that QSYQ inhibited the expression of cluster of differentiation 36, promoted the expression of forkhead box P3 and decreased interleukin-17A expression. Western blots of spleen showed that QSYQ decreased the expression of mothers against decapentaplegic homolog 2/3 and forkhead box P3, as well as attenuated the expression of spleen interleukin-6, RAR-related orphan receptor gamma and interleukin-17A.
QSYQ exerted an anti-atherosclerosis effect by promoting regulatory T cells in atherosclerotic lesion, inhibiting T helper 17 cells in plaque and spleen and accelerating liver cholesterol excretion.
本研究旨在探讨芪参益气滴丸（QSYQ）对动脉粥样硬化抑制作用潜在的免疫调节机制。
雄性载脂蛋白E（ApoE）小鼠采用西式饮食并接受QSYQ治疗8周。动脉粥样硬化检测显示，QSYQ减轻了斑块形成并降低了血液中低密度脂蛋白胆固醇水平。QSYQ治疗不影响体重，但降低了肝脏重量与体重的比值。肝脏的蛋白质免疫印迹分析表明，QSYQ增加了肝脏X受体α和ATP结合盒转运体G超家族成员5的表达。动脉粥样硬化主动脉的蛋白质免疫印迹分析显示，QSYQ抑制了分化簇36的表达，促进了叉头框蛋白P3的表达，并降低了白细胞介素-17A的表达。脾脏的蛋白质免疫印迹分析表明，QSYQ降低了果蝇原癌基因产物2/3和叉头框蛋白P3的表达，并减弱了脾脏白细胞介素-6、视黄酸相关孤儿受体γ和白细胞介素-17A的表达。
QSYQ通过促进动脉粥样硬化病变中的调节性T细胞、抑制斑块和脾脏中的辅助性T细胞17以及加速肝脏胆固醇排泄发挥抗动脉粥样硬化作用。
